Summary: OVERPRICED
Score: 8/20
MOS: -110%
Share Price: $110
Sticker Price: $52
Is DGX (Quest Diagnostics) a good investment?
Quest Diagnostics was founded in 1967 and is based out of Secaucus, NJ. Quest is a clinical laboratory that operations in the US, Mexico, Puerto Rico, and Brazil. They specifically offer access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders, and COVID-19.
Quest was the first west coast lab to offer broad-based COVID-19 testing but unfortunately COVID-19 tests don’t exactly have a wide moat. Many healthcare operations and laboratories have the ability to test COVID-19. When conducting a simple google search in your area, dozens of testing centers nearby will appear on Google Maps.
Some of Quest’s top competitors include:
Invitae (NVTA)
Summary: OVERPRICED
Score: 5/20
Share Price: $33
Sticker Price: $8
Abbott (ABT)
Summary: OVERPRICED
Score: 9/20
Share Price: $105
Sticker Price: $11
Thermo Fisher Scientific (TMO)
Summary: OVERPRICED
Score: 9/20
Share Price: $436
Sticker Price: $516
Is Quest a good investment? Overall, Quest and their competitors do not pass the Tykr test. My advice is to keep your distance. With a score of 8/20, Quest’s financials show that this stock is too much of a risk. With a share price of $110 and sticker price of $52, this stock could be on its way down.
—
The Summary, Score, and MOS of this stock may have changed since the posting of this review. Please login to Tykr to see up-to-date information.